GSK Bags Tesaro For $5B As It Leaps Back Into Commercial Oncology, Beefs Up Cancer Drug Pipeline

December 05, 2018 | GlaxoSmithKline has struck a deal to buy Tesaro in a $5.1 billion deal that will vault the pharma giant into the commercial oncology market as it stakes out a big new role for itself in the booming cancer field. Endpoints News